SNS851

Phase 1Small molecule

OOneness Biotech Co., Ltd.

SNS851 is one of 15 small molecule programs targeting Metabolic Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metabolic DiseaseRecruiting

Metabolic DiseasePhase 1

Recruiting

Competition

Competitive Landscape

17 competitors in Metabolic Disease

#DrugCompanyPhaseTrials

Tivicay

GSK

Approved

1 2

Onglyza

Farxiga

Avandia

Altoprev

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Tricor

Glucophage

Ozempic

1 9

Mounjaro

Eli Lilly

Preclinical

1 10

Andriol

AAuxilium

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Metabolic Disease

NCT07417124

Clinical

Trials by Indication[1]

Metabolic Disease1 trial

A First-in-Human Study to Assess the Safety and Tolerability of Single and Multiple Doses of SNS851

Recruiting·OOneness Biotech Co., Ltd.·Phase 1·NCT07417124·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SNS851. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SNS851 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SNS851. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Oneness Biotech Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: OOneness Biotech Co., Ltd.

SNS851

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Metabolic Disease1 trial

References

Drug Info

Quick Facts

Related News